Banking on Shanghai's biotech boom, this Eli Lilly-backed player grabs $100M to push next-gen I/O therapies
Every six months for the past two years or so, five renowned scientists and biotech vets — David Shen of NGM Bio, Arlene Sharpe and Vijay …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
